| Eugene Oppman Apoc Inc | |
|
312 Martin Luther King Jr St, Independence, LA 70443-2387 | |
| (985) 878-1066 | |
| Not Available |
| Full Name | Eugene Oppman Apoc Inc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 312 Martin Luther King Jr St, Independence, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588832919 | NPI | - | NPPES |
| 1396724639 | Other | LA | INDIVIDUAL NPI |
| 1370771 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 1033-109T (Louisiana) | Primary |
| Provider Name | Eugene G Oppman |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1396724639 PECOS PAC ID: 3870584287 Enrollment ID: I20040927000027 |
News Archive
Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).
Approximately every fourth working aged Finn experiences symptoms of burnout that include exhaustion, cynicism and reduced professional efficacy and often also difficulties in concentration and memory.
A new IU study examining effects of low-level developmental lead exposure in mice could explain why some people dependent on alcohol return to using.
Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eugene Oppman Apoc Inc Po Box 10190, New Orleans, LA 70181-0190 Ph: (985) 878-1066 | Eugene Oppman Apoc Inc 312 Martin Luther King Jr St, Independence, LA 70443-2387 Ph: (985) 878-1066 |
News Archive
Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).
Approximately every fourth working aged Finn experiences symptoms of burnout that include exhaustion, cynicism and reduced professional efficacy and often also difficulties in concentration and memory.
A new IU study examining effects of low-level developmental lead exposure in mice could explain why some people dependent on alcohol return to using.
Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.
› Verified 4 days ago
Dr. Eugene Gary Oppman, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 312 Martin Luther King Jr St, Independence, LA 70443 Phone: 985-878-1066 Fax: 504-617-6303 |